Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › emphysema

Emphysema

Part of Chronic Obstructive Pulmonary Disease

Subtypes of Emphysema

Severe Lung Emphysema 1

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for emphysema

32 trials tracked for emphysema: 9 in phase 3 or 4 and 3 with published results. The most-cited published study has 509 citations.

32Trials tracked
9Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 8 Phase 3 1 Phase 2 6 Other / NA 17
  1. Phase 4 Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency. Completed · 509 cited
  2. Phase 4 Hypoxic Pulmonary Vasoconstriction Pilot Study Completed · 114 cited
  3. Phase 4 Losartan Effects on Emphysema Progression Completed · 26 cited
  4. Phase 4 Efficacy of Losartan in Preventing Progression of COPD Completed
  5. Phase 4 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis Completed
  6. Phase 4 Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Completed
Show 26 more trials
  1. Phase 4 Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency Completed
  2. Phase 4 Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD) Completed
  3. Phase 3 Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease Completed
  4. Phase 2 Anti-Platelets in Chronic Obstructive Pulmonary Disease Completed
  5. Phase 2 Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Completed
  6. Phase 2 Sildenafil for Chronic Obstructive Pulmonary Disease Completed
  7. Phase 2 Prostaglandin Inhibition for Emphysema Completed
  8. Phase 2 Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies Completed
  9. Phase 2 Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency Completed
  10. N/A Doxycycline for COPD in HIV-Infected Patients Completed
  11. N/A Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema Completed
  12. N/A Regulation of the Release of Inflammatory Mediators From Lung Macrophages. Completed
  13. N/A Advancing Symptom Alleviation With Palliative Treatment Completed
  14. N/A A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) Completed
  15. N/A Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  16. N/A Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability Completed
  17. N/A Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD) Completed
  18. N/A Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations Completed
  19. N/A Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy Completed
  20. N/A Home Pulmonary Rehabilitation for COPD Completed
  21. N/A Alpha-1 Carrier Genomics Study Completed
  22. N/A Leukocyte Function in Asthma and COPD Completed
  23. N/A Macrophage Phagocytosis in COPD Completed
  24. N/A The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD Completed
  25. N/A Implementing and Evaluating the Genie Tool in COPD Completed
  26. N/A Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Emphysema: what the trials found

Alpha1-proteinase inhibitor demonstrated a statistically significant reduction in the annual rate of change in lung density (p=0.029) 8. However, other trials evaluating Alpha1-proteinase inhibitor did not find statistically significant changes in the rate of change or absolute change in adjusted lung density 2.

Sildenafil administration was associated with a significant increase in perfused blood volume assessed for lung inflammation (p<0.05) 3.

Arformoterol tartrate inhalation solution showed no statistically significant difference in FEV1 at the 24-hour trough (p=0.073) or peak change over 12 hours (p=0.060) 9. Clinical data also indicate that Arformoterol tartrate is associated with specific rates of adverse events and usage patterns for rescue medications like Ipratropium Bromide and Albuterol/Levalbuterol 10.

Losartan did not show statistically significant changes in mean pct950 (p=0.133), FEV1 percent predicted (pre- or post-bronchodilator) 4, or change in percent emphysema on CT scan (p=0.06) and FEV1 (L) 7.

Recent results — preliminary, needs further review

  • A Phase 2 trial using a placebo showed no significant changes in pulmonary microvascular blood volume (p=0.84; p=0.98) or oxygen saturation (p=0.75) 1.

For the clinician treating this condition

  • Alpha1-proteinase inhibitor shows statistically significant evidence for slowing the annual rate of change in lung density, though results across different trials are inconsistent regarding absolute changes [2, 8].
  • Sildenafil is associated with increased perfused blood volume related to lung inflammation 3.
  • Arformoterol tartrate inhalation solution demonstrates consistent usage patterns and specific adverse event profiles, but did not reach statistical significance for peak FEV1 improvements in the studied timeframe [9, 10].
  • Losartan did not demonstrate statistically significant improvements in FEV1 or emphysema percentage on CT scans in the evaluated trials [4, 7].

AI synthesis of 8 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Endobronchial valve treatment triples peri-procedural mortality odds in severe emphysema
Pulmonology & Critical Care Meta-analysis
Endobronchial valve treatment triples peri-procedural mortality odds in severe emphysema Endobronchial Valve Treatment Shows Mixed Results for Emphysema Mortality
This meta-analysis of 819 patients with severe emphysema found that endobronchial valve (EBV) treatment significantly increased peri-procedu…
New analysis of 819 patients shows that while endobronchial valves do not change overall mortality, risks are higher in the first 90 days.
Sep 2, 2026
Combined lung cancer resection and LVRS shows 7.3% mortality estimate with significant FEV1 improvement
Oncology Meta-analysis
Combined lung cancer resection and LVRS shows 7.3% mortality estimate with significant FEV1 improvement Combined lung surgery for cancer and emphysema shows mixed results
This meta-analysis of 113 participants evaluates combined lung cancer resection and lung volume reduction surgery (LVRS) for patients with s…
A combined surgical approach for patients with both lung cancer and emphysema may improve breathing but carries significant risks.
Frontiers Aug 20, 2026
Personalised CT feedback fails to boost quit rates overall in lung cancer screening
Pulmonology & Critical Care RCT
Personalised CT feedback fails to boost quit rates overall in lung cancer screening Personalized images of lung damage do not increase smoking quit rates
In a randomized controlled trial of 1003 individuals attending lung cancer screening, a personalised smoking cessation package with annotate…
Showing patients their own lung scans does not improve overall smoking quit rates, though it may show different results for women.
Aug 15, 2026
Retrospective analysis shows machine learning improves CT-based airway and emphysema mapping
Radiology & Imaging
Retrospective analysis shows machine learning improves CT-based airway and emphysema mapping New AI Scan Detects Lung Damage More Accurately Than Old Tech
This retrospective analysis evaluates a new feature-based parametric response mapping (PRMD) method using machine learning on CT scans for C…
A new AI tool scans lungs more accurately than old methods, helping doctors spot COPD damage even when images are noisy.
medRxiv Apr 27, 2026
Non-powered stapler linked to fewer postoperative air leaks than powered stapler in severe emphysema LVRS
Pulmonology & Critical Care RCT
Non-powered stapler linked to fewer postoperative air leaks than powered stapler in severe emphysema LVRS Small study compares stapler types for lung surgery in severe emphysema patients
A single-blinded RCT of 19 patients with severe lung emphysema undergoing lung volume reduction surgery found the non-powered AEON Endostapl…
A non-powered surgical stapler cut the rate of air leaks after lung surgery for severe emphysema by nearly half compared to a powered staple…
Apr 5, 2026